Inspire Medical Systems, Inc.

The company develops and commercializes minimally invasive neurostimulation technologies for patients with obstructive sleep apnea. Its main product is the Inspire system, including the Inspire IV and Inspire V models, which monitors breathing and delivers mild hypoglossal nerve stimulation to keep airways open during sleep. The system includes an implantable neurostimulator, leads, a remote control, and the digital SleepSync management platform. The company sells its medical devices to hospitals and ambulatory surgery centers, while collaborating with ear, nose, and throat doctors, sleep centers, and patients.

As of December 31, 2025, the firm maintains 295 sales territories across the United States and 21 international territories. It markets directly to healthcare providers in the United States and select European countries, and uses distributors in Asian markets including Japan, Singapore, Hong Kong, and Thailand. More than 125,000 patients have received the therapy across the United States, Europe, and Asia. The provided text does not state the company's headquarters.

Summary of the business section of Inspire Medical Systems's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 1,333 employees, of which 1,243 are in the U.S., 83 are in Europe and 7 are in Japan.”